The neuropathology of manganese-induced Parkinsonism.

Olfactory dysfunction in Parkinson disease. Nat Rev Neurol (2012) 1.73

Manganese and Parkinson's disease: a critical review and new findings. Environ Health Perspect (2010) 1.66

Manganese and its role in Parkinson's disease: from transport to neuropathology. Neuromolecular Med (2009) 1.54

Brain deposition and neurotoxicity of manganese in adult mice exposed via the drinking water. Arch Toxicol (2013) 1.44

Genetic advances in the study of speech and language disorders. Neuron (2010) 1.33

The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci (2011) 1.31

Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem (2008) 1.31

Increased APLP1 expression and neurodegeneration in the frontal cortex of manganese-exposed non-human primates. J Neurochem (2008) 1.30

Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health (2011) 1.27

Occupational factors and risk of Parkinson's disease: A population-based case-control study. Am J Ind Med (2010) 1.26

Oxidative damage and neurodegeneration in manganese-induced neurotoxicity. Toxicol Appl Pharmacol (2009) 1.23

Manganese neurotoxicity: lessons learned from longitudinal studies in nonhuman primates. Environ Health Perspect (2008) 1.19

Age-dependent susceptibility to manganese-induced neurological dysfunction. Toxicol Sci (2009) 1.16

Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci (2015) 1.07

Pathophysiology of manganese-associated neurotoxicity. Neurotoxicology (2011) 1.06

Manganese exposure is cytotoxic and alters dopaminergic and GABAergic neurons within the basal ganglia. J Neurochem (2009) 1.06

SLC30A10 is a cell surface-localized manganese efflux transporter, and parkinsonism-causing mutations block its intracellular trafficking and efflux activity. J Neurosci (2014) 1.05

Manganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates. Front Aging Neurosci (2013) 1.04

Acquired hepatocerebral degeneration. J Neurol (2009) 0.98

White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome. Brain (2010) 0.98

Synergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia. J Neurochem (2009) 0.92

Microglia enhance manganese chloride-induced dopaminergic neurodegeneration: role of free radical generation. Exp Neurol (2009) 0.92

Manganese exposure induces α-synuclein aggregation in the frontal cortex of non-human primates. Toxicol Lett (2012) 0.91

Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest (2013) 0.90

Manganese-Induced Parkinsonism due to Ephedrone Abuse. Parkinsons Dis (2011) 0.90

Effects of manganese on tyrosine hydroxylase (TH) activity and TH-phosphorylation in a dopaminergic neural cell line. Toxicol Appl Pharmacol (2011) 0.90

World Health Organization discontinues its drinking-water guideline for manganese. Environ Health Perspect (2012) 0.89

Gender and manganese exposure interactions on mouse striatal neuron morphology. Neurotoxicology (2011) 0.88

Manganese exposure induces microglia activation and dystrophy in the substantia nigra of non-human primates. Neurotoxicology (2010) 0.87

Waterborne manganese exposure alters plasma, brain, and liver metabolites accompanied by changes in stereotypic behaviors. Neurotoxicol Teratol (2011) 0.87

Neuromotor function in ship welders after cessation of manganese exposure. Int Arch Occup Environ Health (2011) 0.86

"Manganese-induced neurotoxicity: a review of its behavioral consequences and neuroprotective strategies". BMC Pharmacol Toxicol (2016) 0.86

The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition. J Neurochem (2010) 0.86

In vivo manganese exposure modulates Erk, Akt and Darpp-32 in the striatum of developing rats, and impairs their motor function. PLoS One (2012) 0.86

Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable Features. Int J Environ Res Public Health (2015) 0.86

Glyphosate, pathways to modern diseases III: Manganese, neurological diseases, and associated pathologies. Surg Neurol Int (2015) 0.85

Intranasal exposure to manganese disrupts neurotransmitter release from glutamatergic synapses in the central nervous system in vivo. Neurotoxicology (2012) 0.85

Manganese exposure inhibits the clearance of extracellular GABA and influences taurine homeostasis in the striatum of developing rats. Neurotoxicology (2010) 0.84

X-ray fluorescence imaging: a new tool for studying manganese neurotoxicity. PLoS One (2012) 0.84

Protective effects of antioxidants and anti-inflammatory agents against manganese-induced oxidative damage and neuronal injury. Toxicol Appl Pharmacol (2011) 0.83

α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. Neurotoxicology (2011) 0.83

Manganism in the 21st century: the Hanninen lecture. Neurotoxicology (2013) 0.83

Gene deletion of nos2 protects against manganese-induced neurological dysfunction in juvenile mice. Toxicol Sci (2011) 0.82

Mitochondrial Redox Dysfunction and Environmental Exposures. Antioxid Redox Signal (2015) 0.82

Manganese uptake and distribution in the brain after methyl bromide-induced lesions in the olfactory epithelia. Toxicol Sci (2010) 0.81

Manganese potentiates LPS-induced heme-oxygenase 1 in microglia but not dopaminergic cells: role in controlling microglial hydrogen peroxide and inflammatory cytokine output. Neurotoxicology (2011) 0.81

A distinct variant of mixed dysarthria reflects parkinsonism and dystonia due to ephedrone abuse. J Neural Transm (Vienna) (2014) 0.81

Structural Elements in the Transmembrane and Cytoplasmic Domains of the Metal Transporter SLC30A10 Are Required for Its Manganese Efflux Activity. J Biol Chem (2016) 0.81

A zebrafish model of manganism reveals reversible and treatable symptoms that are independent of neurotoxicity. Dis Model Mech (2014) 0.80

Changes in the striatal proteome of YAC128Q mice exhibit gene-environment interactions between mutant huntingtin and manganese. J Proteome Res (2012) 0.80

Chronic exposure to manganese alters brain responses to amphetamine: a pharmacological magnetic resonance imaging study. Toxicol Sci (2010) 0.80

BDNF and Huntingtin protein modifications by manganese: implications for striatal medium spiny neuron pathology in manganese neurotoxicity. J Neurochem (2014) 0.79

Expression and Transport of α-Synuclein at the Blood-Cerebrospinal Fluid Barrier and Effects of Manganese Exposure. ADMET DMPK (2015) 0.78

Manganese induces oxidative stress, redox state unbalance and disrupts membrane bound ATPases on murine neuroblastoma cells in vitro: protective role of silymarin. Neurochem Res (2011) 0.78

Manganese-Induced Parkinsonism Is Not Idiopathic Parkinson's Disease: Environmental and Genetic Evidence. Toxicol Sci (2015) 0.78

Manganese-induced atypical parkinsonism is associated with altered Basal Ganglia activity and changes in tissue levels of monoamines in the rat. PLoS One (2014) 0.77

Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model. Biochim Biophys Acta (2017) 0.77

Association of hair manganese level with symptoms in attention-deficit/hyperactivity disorder. Psychiatry Investig (2015) 0.76

Disease-Toxicant Interactions in Parkinson's Disease Neuropathology. Neurochem Res (2016) 0.76

Expression Profiles of Long Noncoding RNAs and Messenger RNAs in Mn-Exposed Hippocampal Neurons of Sprague-Dawley Rats Ascertained by Microarray: Implications for Mn-Induced Neurotoxicity. PLoS One (2016) 0.75

Manganese inhalation as a Parkinson disease model. Parkinsons Dis (2010) 0.75

Association of Serum Manganese Levels with  Alzheimer's Disease and Mild Cognitive Impairment:  A Systematic Review and Meta-Analysis. Nutrients (2017) 0.75

The interactome of the copper transporter ATP7A belongs to a network of neurodevelopmental and neurodegeneration factors. Elife (2017) 0.75

Hypothyroidism induced by loss of the manganese efflux transporter SLC30A10 may be explained by reduced thyroxine production. J Biol Chem (2017) 0.75

Drosophila melanogaster Models of Metal-Related Human Diseases and Metal Toxicity. Int J Mol Sci (2017) 0.75

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52

Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86

Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol (2004) 6.14

Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84

Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67

"Psychogenic movement disorders": they are what they are. Mov Disord (2014) 2.56

Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem (2007) 2.40

The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol (2008) 2.27

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09

Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord (2008) 1.98

Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol (2003) 1.91

Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90

Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord (2007) 1.85

Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA (2004) 1.71

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63

Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol (2004) 1.55

Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med (2003) 1.52

Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol (2008) 1.47

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39

The pathogenesis of cell death in Parkinson's disease. Neurology (2006) 1.38

Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci (2002) 1.35

Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol (2005) 1.27

Early single cell bifurcation of pro- and antiapoptotic states during oxidative stress. J Biol Chem (2004) 1.24

Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem (2002) 1.22

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol (2002) 1.22

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord (2007) 1.17

Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol (2003) 1.15

Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport (2002) 1.15

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology (2013) 1.14

Movement disorders and AIDS: a review. Parkinsonism Relat Disord (2004) 1.12

Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett (2002) 1.11

Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol (2003) 1.10

Overexpression of torsinA in PC12 cells protects against toxicity. J Neurochem (2004) 1.08

Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging (2005) 1.08

Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study. J Neurosurg (2004) 1.05

p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem (2006) 0.99

Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J (2003) 0.97

Proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol (2006) 0.95

Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem (2008) 0.95

Treatment of levodopa-induced motor complications. Mov Disord (2008) 0.95

Clinical usefulness of the Parkinson's disease sleep scale. Parkinsonism Relat Disord (2005) 0.92

Open-label surgical trials for Parkinson disease: time for reconsideration. Ann Neurol (2011) 0.91

Stem cell treatment for Parkinson's disease: an update for 2005. Curr Opin Neurol (2005) 0.90

Sleepiness in Parkinson's disease: a controlled study. Mov Disord (2003) 0.90

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord (2004) 0.89

Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology (2006) 0.88

Proteasomal dysfunction in sporadic Parkinson's disease. Neurology (2006) 0.88

Modeling Parkinson's disease. Ann Neurol (2009) 0.88

Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? Exp Neurol (2007) 0.88

Neuroprotection for Parkinson's disease: prospects and promises. Ann Neurol (2003) 0.87

Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol (2003) 0.87

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain (2002) 0.85

Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy. Mt Sinai J Med (2007) 0.84

Levodopa toxicity and Parkinson disease: still a need for equipoise. Neurology (2011) 0.84

Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Mov Disord (2013) 0.83

Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord (2011) 0.83

Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther (2003) 0.82

Levodopa-induced dyskinesias in the absence of nigrostriatal degeneration. Mov Disord (2013) 0.81

Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites. Eur J Neurosci (2004) 0.80

Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology (2004) 0.79

Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gait. J Neurophysiol (2009) 0.78

Stem cells for Parkinson's disease: advancing science but protecting patients. Mov Disord (2012) 0.78

Prevalence of movement disorders in an elderly nursing home population. Arch Gerontol Geriatr (2007) 0.78

Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord (2014) 0.78

Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease. Mov Disord (2011) 0.78

A model-based approach for assessing parkinsonian gait and effects of levodopa and deep brain stimulation. Conf Proc IEEE Eng Med Biol Soc (2006) 0.78

Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease. Arch Neurol (2005) 0.77

Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol (2012) 0.77

Emotional processing affects movement speed. J Neural Transm (Vienna) (2011) 0.77

Parkinson's disease: unresolved issues. Ann Neurol (2008) 0.77

Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. Can J Neurol Sci (2005) 0.77

Neuroprotective agents in Parkinson's disease: clinical evidence and caveats. Neurol Clin (2004) 0.76

Reply to: psychogenic movement disorders: what's in a name? Mov Disord (2014) 0.76

A colonic biomarker of Parkinson's disease? Mov Disord (2012) 0.76

Technical advances in deep brain stimulation: how far is enough? Mov Disord (2012) 0.75

Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Mov Disord (2010) 0.75

A changing journal for a changing field. Mov Disord (2010) 0.75

Preserved emotional modulation of motor response time despite psychomotor slowing in young-old adults. Int J Neurosci (2011) 0.75

Scientific perspectives. Mov Disord (2014) 0.75

Melvin David Yahr, MD (1917-2004). Neurology (2004) 0.75

Movement disorders 2011--the state of the journal. Mov Disord (2011) 0.75